Sector: Medtech, Gastrointestinal
Location: Texas, USA / Nijmegen, Netherlands
Investment Stage: Early
Investment Status: Liquidated
Year Invested: 2016
EndoStim was a medical device company based in Dallas, Texas, and Nijmegen, The Netherlands, developing and commercializing a treatment for gastroesophageal reflux disease (GERD). EndoStim’s neurostimulation technology was designed to provide long-term reflux control by restoring normal oesophageal function. The therapy directly targeted the patient’s weak or dysfunctional lower oesophageal sphincter (LES) muscle between the stomach and the oesophagus, often the underlying cause of reflux. The system consisted of an implantable neurostimulator and a lead that delivered low energy stimulation to the LES. The EndoStim procedure was designed to preserve natural anatomy in order to reduce or avoid typical gastrointestinal side effects of traditional anti-reflux surgery.
See Endostim related news here